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Human β-defensin-2 production from  
S. cerevisiae using the repressible MET17 
promoter
Thea S. B. Møller1,2, Joanna Hay1, Malcolm J. Saxton1, Karen Bunting1, Evamaria I. Petersen2, Søren Kjærulff1 
and Christopher J. A. Finnis1*
Abstract 
Background: Baker’s yeast Saccharomyces cerevisiae is a proven host for the commercial production of recombinant 
biopharmaceutical proteins. For the manufacture of heterologous proteins with activities deleterious to the host it can 
be desirable to minimise production during the growth phase and induce production late in the exponential phase. Pro-
tein expression by regulated promoter systems offers the possibility of improving productivity in this way by separating 
the recombinant protein production phase from the yeast growth phase. Commonly used inducible promoters do not 
always offer convenient solutions for industrial scale biopharmaceutical production with engineered yeast systems.
Results: Here we show improved secretion of the antimicrobial protein, human β-defensin-2, (hBD2), using the 
S. cerevisiae MET17 promoter by repressing expression during the growth phase. In shake flask culture, a higher final 
concentration of human β-defensin-2 was obtained using the repressible MET17 promoter system than when using 
the strong constitutive promoter from proteinase B (PRB1) in a yeast strain developed for high-level commercial 
production of recombinant proteins. Furthermore, this was achieved in under half the time using the MET17 promoter 
compared to the PRB1 promoter. Cell density, plasmid copy-number, transcript level and protein concentration in the 
culture supernatant were used to study the effects of different initial methionine concentrations in the culture media 
for the production of human β-defensin-2 secreted from S. cerevisiae.
Conclusions: The repressible S. cerevisiae MET17 promoter was more efficient than a strong constitutive promoter for 
the production of human β-defensin-2 from S. cerevisiae in small-scale culture and offers advantages for the commer-
cial production of this and other heterologous proteins which are deleterious to the host organism. Furthermore, the 
MET17 promoter activity can be modulated by methionine alone, which has a safety profile applicable to biopharma-
ceutical manufacturing.
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Background
Saccharomyces cerevisiae has a long safe history of use 
for the production of biopharmaceutical proteins and 
has a rich density of knowledge detailing its genetics, 
biochemistry, physiology and large-scale fermentation 
performance. Many different promoters have been used 
to successfully drive the expression of foreign genes 
in S.  cerevisiae. However, the choice of promoter for 
heterologous gene expression can affect the product yield 
greatly [1, 2]. Expression using regulated promoter sys-
tems is advantageous for proteins which are toxic to the 
host cell as this allows controlled timing of gene expres-
sion and higher production levels. Regulated expression 
can be achieved through manipulation of the growth 
medium by adding metabolites. The galactose (GAL1-
10) promoters are commonly used to allow regulation 
of the target gene by the carbon source; using galactose 
for induction and glucose for repression [3]. However, 
the commonly used galactose promoter systems are not 
always applicable for industrial expression systems, as 
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the S.  cerevisiae strains used may not respond well to 
galactose. In addition, regulation of these promoters may 
interfere with the cellular metabolism and in many cases 
the regulation is not tight enough to completely shut 
off transcription. This issue was addressed by use of the 
tetracycline (Tet-On/Off) promoters, which are either 
inducible or repressible [4]. Here, gene expression is acti-
vated as a result of binding of the Tet-Off or Tet-On pro-
tein to an element located within an inducible promoter. 
One advantage of this system is that promoter regulation 
with the tetracycline derivative, doxycycline does not 
interfere with the yeast cellular metabolism. However, 
doxycycline is not ideal for use in biopharmaceutical 
processes and its regulation needs tetracycline-regulated 
activators and repressors, which require a specific strain 
background or additional manipulations of the strains in 
use [4, 5]. Consequently, alternative promoter systems 
with safe and simple regulation are desirable for some 
large scale biopharmaceutical processes.
In S. cerevisiae, the MET17 gene (also known as MET15 
and MET25) encodes O-acetylhomoserine sulfhydrolase 
[6, 7] and its promoter displays repression of transcrip-
tional expression in the presence of methionine [8] or 
S–adenosylmethionine (SAM) [9, 10]. MET17 catalyses 
the last step of the sulfate assimilation pathway in S. cer-
evisiae, which is the incorporation of sulfide into a car-
bon chain [7]. The promoter is efficiently and strongly 
repressed at high methionine concentrations with the 
expression of O-acetylhomoserine sulfhydrolase only 
occurring below 0.05  mM methionine [6, 7, 11]. Utilis-
ing media with the correct concentration of methionine, 
the MET17 promoter has been used previously to express 
human serum albumin (HSA) and albumin fusion pro-
teins, including repressing production of glucagon-HSA 
in early log phase with expression in late log phase [6]. 
This separation of the growth and production phases may 
be especially useful for expressing proteins that are toxic 
to the yeast host, which are best produced in the late log 
phase. However, a separation in growth and production 
phases cannot be achieved using constitutive promot-
ers, where the secretion of toxic, or even relatively non-
toxic proteins, can be deleterious to the host resulting in 
reduced product yields. Here, the adverse effects of the 
recombinant hBD2 on the host may be either intracel-
lular during secretion, or extracellular due to its accu-
mulation to toxic levels in the growth media. Compared 
to inducible systems such as the galactose system, the 
MET17 promoter does not require a change in carbon 
source that may potentially slow growth, or the addition 
of an inducing metabolite [6]. This system is based upon 
the consumption of methionine from the media leading 
to subsequent expression of the gene of interest down-
stream of the MET17 promoter. In the past, the MET17 
promoter has been used to produce several heterolo-
gous proteins under derepressing conditions, including 
β-galactosidase [12], CaArn1, a siderophore transporter 
from Candida albicans [13], green fluorescent protein 
(GFP) and GFP fusions [14], and human albumin and 
albumin fusions [6].
Here we describe the use of the repressible MET17 pro-
moter for the secretion of human β-defensin-2 in shake 
flask cultures (SFC) using a highly productive S. cerevi-
siae strain. This yeast strain was initially developed for 
the secretion of recombinant human albumin (rHA); 
however, studies have shown that it can also be used to 
express a diverse range of heterologous proteins [15]. 
hBD2 belongs to the intriguing class of antimicrobial and 
immunomodulatory peptides called defensins. Defensins 
are small cationic and cysteine-rich peptides that play a 
crucial role in the host defence against microorganisms 
[16, 17]. hBD2 is a 41 amino acid peptide first charac-
terised in psoriatic skin, which has been shown to be 
active against Gram-negative (E. coli, P. aeruginosa) and 
Gram-positive (S. aureus) bacteria as well as yeast (C. 
albicans, C. krusei, C. parapsilosis) [18–20]. The action 
of defensins against microorganisms generally involves 
membranolytic disruption, permeability, or pore forma-
tion [21]. Their amino acid composition, amphipathic-
ity, cationic charge and size allow them to attach to and 
insert into membrane bilayers to form pores [22].
Heterologous expression systems have the potential to 
provide hBD2 for both clinical research and therapeu-
tic applications. However, the issues of host cell toxicity, 
proteolytic degradation, folding and low yields must be 
overcome to provide a suitable platform for commercial 
production. To date, recombinant hBD2 has predomi-
nantly been produced from inducible E. coli expression 
systems as a fusion protein requiring in  vitro cleav-
age [23]. Subsequent oxidation may also be needed, for 
which yields of 1–2  mg final product per litre of bacte-
rial culture have been reported [24]. However, soluble 
active hBD2 can also be obtained from fusion proteins 
without the need for refolding, where yields estimated 
to be around 100 mg/L purified mature hBD2 have been 
obtained after enterokinase cleavage [25]. In contrast, 
S. cerevisiae offers the advantage of secreting fully folded 
mature bioactive hBD2 into the culture medium at rela-
tively high product titres without the need for costly 
in vitro processing.
Here we report that the repressible MET17 promoter 
produced the highest levels of hBD2 under initially 
repressing conditions, which was achieved in half the 
incubation time compared to the strong constitutive 
PRB1 promoter in a yeast system modified for high-level 
production of biopharmaceutical proteins. Normally, 
the PRB1 promoter is regulated by carbon and nitrogen 
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sources as well as growth phase, which results in a tran-
scriptional derepression of the PRB1 promoter as the 
cells approach the stationary phase of growth [26]. How-
ever random mutagenesis of this proprietary yeast strain 
produced a constitutive PRB1 promoter system, which 
allows expression of the target protein during exponen-
tial growth as well as during late exponential growth [27].
Results
High‑level expression of human β‑defensin‑2 from the 
MET17 promoter is induced by methionine depletion
To determine if the repressible MET17 promoter was 
more efficient for hBD2 expression than the strong con-
stitutive PRB1 promoter, expression plasmids were pro-
duced harbouring the gene for hBD2 downstream of 
either the MET17 or PRB1 promoter. An expression plas-
mid comprising the MET17 promoter upstream of the 
rHA gene was also made to compare the expression of a 
non-toxic protein to that of a toxic protein. A low pro-
ductivity S. cerevisiae strain, DB1 and a high productiv-
ity S. cerevisiae strain, DYB7, were used for these studies 
(Table 1).
Shake flask cultures of yeast strains were grown in 
non-repressing (methionine-free medium) and repress-
ing (1000  µM initial methionine concentration) con-
ditions to control protein production. Analysis of the 
SFC supernatants of DYB7 [pDB3936:GR:pDB4351], 
expressing hBD2 from the MET17 promoter, by SDS-
PAGE (Fig. 1) and ultra-performance liquid chromatog-
raphy mass spectrometry (UPLC-MS) (Fig.  2) revealed 
that the hBD2 expression was significantly improved 
by initial repression of the MET17 promoter. Results 
for the PRB1 promoter driven constructs confirmed 
that derepression only occurred with the MET17 pro-
moter constructs. The UPLC-MS data indicated that a 
higher hBD2 concentration was obtained in DYB7 using 
the MET17 promoter repressed by 1000  µM methio-
nine compared to the PRB1 promoter in less than half 
the incubation time (Fig.  2a, b). The hBD2 yield using 
the MET17 promoter was estimated to be approxi-
mately double that of the PRB1 promoter after 70  h. 
This demonstrated that the expression of antimicrobial 
defensin hBD2 from the repressible MET17 promoter 
was advantageous and resulted in a higher overall yield 
(g/L/h), an important factor for the economics of biop-
harmaceutical manufacturing.
In order to demonstrate the effect of strain optimisa-
tion from successive rounds of chemical mutagenesis and 
selection, production of hBD2 by the MET17 promoter 
was also analysed in the original progenitor strain DB1 
and compared to a mutated high-level production strain 
DYB7 [27–30]. In SFC, DYB7 showed an approximate 
four-fold increase in hBD2 production levels compared 
to the original progenitor strain DB1, under initially 
repressing conditions (Fig. 2a, c). Furthermore, the ben-
efits of repressing hBD2 expression early in the growth 
phase were greater in the higher productivity strain 
DYB7.
Recombinant human albumin (rHA) expression from 
the MET17 promoter was used as a control for expres-
sion of a non-toxic protein compared to hBD2 (Fig. 2d). 
Similar rHA protein concentrations were obtained after 
120  h of expression regardless of whether the MET17 
promoter was repressed or not in DYB7. Therefore, this 
UPLC–MS data indicates that the MET17 promoter is a 
valuable tool for the production of toxic proteins in this 
expression system.
High hBD2 mRNA levels were obtained from a derepressed 
MET17 promoter
Derepression of the MET17 promoter was demonstrated 
in quantitative RNA studies from both S. cerevisiae DB1 
and DYB7 by marked increases in the hBD2 mRNA levels 
during the exponential growth phase when methionine 
was initially present in the media (Fig. 3a, c). This increase 
in mRNA was likely to be caused by the derepression of 
the MET17 promoter as it was induced by methionine 
depletion during cell growth. It was observed that the 
maximum hBD2 transcript levels from the MET17 pro-
moter occurred earlier for DB1 than the higher produc-
tivity strain DYB7, which can be attributed to growth 
rate differences between these strains (see Fig.  5a, c). 
Significantly lower transcript levels were seen in the cul-
tures without methionine in the media, which indicated 
that a higher overall mRNA level was obtained from an 
initially repressed MET17 promoter. The transcript lev-
els from the PRB1 promoter-driven construct confirmed 
that derepression was specific to the MET17 promoter 
constructs, as the PRB1 promoter was not affected by the 
methionine concentrations used in this study. Changes in 
the transcript levels throughout the expression study are 
Table 1 Yeast strains used in this work
Strain Known genotype Reference
DB1 cir0, MATa, leu2-3, leu2-112 [27]
DBY7 rHA-overproducing strain derived from DB1 by 
chemical mutagenesis. cir0, MATa, leu2-3, leu2-112, 
ubc4, ura3, yap3::URA3, lys2, hsp150::LYS2
[39]
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attributed to changing environmental conditions during 
these batch cultures.
A verification of two endogenous controls was per-
formed to demonstrate which one was the most suit-
able endogenous control for the type of assay performed 
(results not shown). ACT1 was chosen due to its history 
of frequent use as an endogenous control in RT-PCR 
experiments [31, 32]. TAF10 (TATA binding protein 
associated factor) was selected based on the research 
by Teste et  al. which demonstrated that it is a suitable 
endogenous control because its expression was the most 
stable under the conditions tested. The transcript levels 
of these genes were analysed by a direct comparison of 
their cycle threshold (Ct), assuming equal Ct for equal 
Fig. 1 hBD2 secretion from yeast strain DYB7 using the MET17 and PRB1 promoters. SDS-PAGE analysis for hBD2 secretion from the MET17 and 
PRB1 promoter with and without methionine applied to the growth media. 15 µL of BMMD SFC supernatant was analysed per lane by SDS-PAGE 
(NuPAGE® 12% Bis–Tris, MES SDS running buffer, Invitrogen). 10 μL SeeBlue® Plus2 Pre-stained protein standard (Invitrogen). Culture samples were 
taken approximate every 24 h during the 5-day incubation. hBD2 is marked with arrows. a Expression of hBD2 from the MET17 promoter under 
non-repressing (0 µM methionine) and initially repressing conditions (1000 µM methionine). b Expression of hBD2 from the PRB1 promoter without 
methionine (0 µM methionine) and with methionine in the media (1000 µM methionine)
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transcript level, since all RT-PCR reactions were per-
formed with equal quantity of total RNA (cDNA). The Ct 
values for TAF10 displayed a smaller variation and gra-
dient than the Ct values for ACT1. Consequently, TAF10 
appeared to be a better endogenous control than ACT1 
for the experiments performed in this study. Based on 
these results TAF10 was used as the endogenous control 
all RT-PCR experiments.
Plasmid copy‑number was affected by promoter activity
Significantly higher relative plasmid copy-numbers were 
obtained in the high productivity strain DYB7, compared 
to the original progenitor strain DB1, which is consistent 
with the ubc4 mutation in DYB7 causing an increased 
plasmid copy–number (Fig. 4) [28]. The results obtained 
through copy-number determination using (RT-PCR) did 
not show a significant difference between cultures with 
and without methionine repression in any strain.
Higher cell densities in hBD2 cultures with a repressed 
MET17 promoter
In small scale cultures, a higher biomass was achieved 
earlier in the exponential growth phase in the repressed 
cultures of both DB1 and DYB7 with hBD2 expression 
from the MET17 promoter (Fig.  5a, c). The repression 
effect was much more pronounced when the yeast cells 
were producing hBD2, compared to the albumin control 
(Fig.  5d), presumably because of the greater burden on 
host cell metabolism. The difference in growth between 
the cultures expressing rHA from the MET17 promoter 
and the cultures expressing hBD2 from the same pro-
moter are consistent with the antimicrobial activity of 
Fig. 2 Relative hBD2 and rHA productivity determined by UPLC-MS analysis. hBD2 and rHA were expressed using either the MET17 or the PRB1 
promoter on 2 µm-based expression plasmids. Plasmids were transformed into S. cerevisiae strain DYB7 or DB1. The transformed yeast were inocu-
lated at OD600 = 0.15 into BMMD SFC without or with 1000 µM methionine and grown for 5 days, while culture samples were taken approximately 
every 24 h. Error bars indicate standard deviations (n = 3). a Expression of hBD2 from the MET17 promoter (pDB3936:GR:pDB4351) under non–
repressing (0 µM methionine) and initially repressing conditions (1000 µM methionine) in DYB7. b Expression of hBD2 from the PRB1 promoter 
(pDB3936:GR:pDB4146) without methionine (0 µM) and with methionine in the media initially (1000 µM) in DYB7. c Expression of hBD2 from the 
MET17 promoter (pDB3936:GR:pDB4351) under non-repressing (0 µM methionine) and initially repressing conditions (1000 µM methionine) in DB1. 
d Expression of rHA from the MET17 promoter (pDB3936:GR:pDB4692) under non-repressing (0 µM methionine) and initially repressing conditions 
(1000 µM methionine) in DYB7
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hBD2 inhibiting the cell growth. The PRB1 promoter 
driven constructs (Fig. 5b) confirmed that the repression 
effect was specific to the MET17 promoter in both low 
and high productivity S. cerevisiae strains. The antimi-
crobial effect of hBD2 was also observed on the growth 
curves of DYB7 when the PRB1 promoter was used com-
pared to the MET17 promoter under initially repressing 
conditions, as a longer lag phase was observed (Fig.  5a, 
b). The growth inhibiting effect of hBD2 production was 
less marked for DB1 than for DYB7 (Fig.  5a, c), poten-
tially due to the faster growth and lower productivity of 
DB1 compared to DYB7, suggesting that exceeding a crit-
ical hBD2 concentration for a given cell density may be 
required for cell growth to be inhibited.
Consequently, a higher biomass was obtained earlier 
using the MET17 promoter initially repressed by methio-
nine, because a separation of the hBD2 production phase 
and the yeast growth phase had been achieved.
Discussion
For the cultures containing 1000  mM methionine in 
the initial medium it is interesting that this does not 
appear to have contributed to a significant increase 
in growth rate compared to the cultures lacking this 
additional nutrient (Fig. 5b, d). Neither does it appear 
to have had a significant effect on the production of 
either hBD2 or rHA (Fig. 2b, d), suggesting it has not 
alleviated a limitation to their secretion. It is however, 
possible that overall protein expression might have 
been affected and background staining of SDS-PAGE 
gels appears to be greater for cultures with 1000  mM 
methionine in the initial media (Fig.  1), which is oth-
erwise a minimal medium with micronutrients sup-
plemented, but devoid of amino acids. If so, this effect 
could add to the stimulatory effect of initial repression 
of hBD2 and further boost the production of the target 
protein.
Fig. 3 Transcript levels determined by real-time PCR. hBD2 was expressed from a 2 µm-based expression plasmid containing either the MET17 or 
PRB1 promoter upstream of the hBD2 gene. These plasmids were transformed into S. cerevisiae strains DYB7 or DB1. The transformed yeast were 
inoculated at OD600 = 0.15 into BMMD SFC without or with 1000 µM methionine and grown for 5 days, while cell pellet samples were taken approx-
imately every 24 h and stored in RNAlater (Invitrogen) before RNA isolation and subsequently cDNA preparation. Error bars indicate coefficient of 
variation (n = 6). The fold difference is relative to the culture without methionine at 24 h in each strain (marked in red). a hBD2 mRNA produced 
from DYB7 with the MET17 promoter under non-repressing (0 µM methionine) and repressing conditions (1000 µM methionine). b hBD2 mRNA 
produced from DYB7 with the PRB1 promoter without methionine added to the media (0 µM) and with added methionine (1000 µM). c hBD2 
mRNA produced from DB1 with the MET17 promoter under non repressing (0 µM methionine) and repressing conditions (1000 µM methionine). 
TAF10 was used as the endogenous control
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It is interesting that the increase in hBD2 expression 
due to initial repression with methionine was so much 
greater for the higher productivity strain DYB7 compared 
to the progenitor strain DB1. This effect might be attrib-
uted to the greater toxicity caused by unregulated higher 
level hBD2 secretion, both intracellularly and also in the 
culture medium, where a threshold hBD2 concentration 
may be required for inhibitory effects on the host. While 
the hBD2 inhibition of Candida species is reported to 
vary considerably between strains in the range of 3.9 µg/
mL to > 250 µg/mL [21], the inhibitory concentration for 
DB1 and DYB7 remains to be defined, and indeed may 
differ due to the mutagenesis perform on DYB7.
Due to the low biomass available at early time points 
in this study, the first transcript data were at 24 h, where 
hBD2 mRNA levels already appeared to be substantially 
higher when methionine was initially present in the cul-
ture media (Fig. 3a, c). Indeed, for both DYB7 and DB1 
the hBD2 transcript levels are higher for the initially 
repressed cultures over the entire time course, suggest-
ing that they had overshot the levels in the non-expressed 
cultures before 24  h. It is possible that by this time the 
increased biomass shown in Fig.  5a, c for the initially 
repressed cultures might alleviate the toxic effects on the 
culture during the next 24 h period when the majority of 
hBD2 was produced (Fig. 2a).
Although it is clear from Fig. 4 that DYB7 has a higher 
plasmid copy number than DB1, the differences between 
repressed and non-repressed cultures with hBD2 
expressed from the MET17 promoter are not signifi-
cant in this study. Further analysis is therefore required 
to establish whether MET17 promoter transcription 
impacts on the transcription of the REP1, REP2, FLP1 
and D genes, which might affect the plasmid copy-num-
ber through their roles controlling plasmid amplification 
and partitioning between mother and daughter cells [33, 
34].
While accurate quantification of the mature hBD2 
expression levels has not been performed in this study, 
the intensity of bands observed by SDS-PAGE suggests 
that high-levels of hBD2 production might be achieved 
during large scale fermentation using this well character-
ised yeast system. Due to the inherent scalability of this 
yeast system and its extensive industrial use for the pro-
duction of human albumin and other recombinant pro-
teins, expression levels of several hundred milligrams per 
litre of this 4.3 KDa protein might be expected, based on 
the equivalent molar expression levels of other proteins 
produced at large scale. Furthermore, the encourag-
ing results described here, suggest that optimisation of 
methionine concentration during high-cell density fer-
mentation could be used to maximise hBD2 yields when 
using the MET17 promoter for large scale production. 
It would also be interesting to know at which time point 
the methionine is depleted and to perform metabolomics 
studies of the intracellular amino acid pools. Overall, 
the successful track–record of this yeast expression plat-
form for the production of approved biopharmaceutical 
proteins and the economic benefits of secreting active 
soluble hBD2, without the need for expensive in  vitro 
processing, make it an attractive candidate for further 
studies to be performed at large scale [35].
Conclusions
Improved production of hBD2 was obtained in shake 
flask culture using the repressible MET17 promoter 
under initially repressing conditions. Higher final con-
centrations of hBD2 were obtained using the repressible 
MET17 promoter compared to the strong constitutive 
PRB1 promoter in a S. cerevisiae strain developed for the 
high–level commercial production of recombinant pro-
teins such as human albumin. Furthermore, the MET17 
promoter system gave a higher hBD2 concentration in 
less than half the time of the PRB1 promoter system in 
this industrial yeast system. It was also shown that pro-
tein production could be controlled by the MET17 pro-
moter through addition of methionine to the media, 
which was advantageous for the production of hBD2 and 
Fig. 4 Relative plasmid gene copy-number determined from real-
time PCRs. The transformed yeast were inoculated at OD600 = 0.15 
into BMMD SFC without or with 1000 µM methionine and grown for 
24 h. The cells were harvested and total DNA was isolated from 10 mL 
cultures. The plasmid names refer to the gap–repair plasmids contain-
ing the expression cassettes with the promoter and the expressed 
protein indicated below, all of which are present in the final pSAC35–
based expression plasmid in yeast. Cultures were grown without and 
with (1000 µM) methionine in the initial media. Error bars represent 
the standard deviation of triplicate analysis of triplicate experimental 
cultures (n = 9). The fold change is relative to DB1 [pDB4351] without 
methionine. FLP1 was used as the single-copy plasmid gene and 
TAF10 was used as the genomic control
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may also be beneficial for other proteins that are del-
eterious to the host. Overall, these results showed great 
potential to using the MET17 promoter for optimising 
production of difficult proteins from S. cerevisiae, which 
is likely to be applicable to large scale manufacturing of 
biopharmaceutical proteins.
Methods
Plasmids and yeast strains
Plasmid pDB4081 contains the PRB1 promoter, a secre-
tory leader sequence, the coding sequence for rHA and 
the S. cerevisiae ADH1 transcription terminator. The 
DNA sequence of the PRB1 promoter is −819 to −1 bps 
from the start codon of the PRB1 gene on Chr. V 40046-
41953 [GeneID:856649]. The DNA sequence for rHA is a 
human albumin sequence [GeneID:213] codon optimised 
for expression in S. cerevisiae. The 5′-end of the human 
albumin DNA was altered to replace the native secretory 
leader sequence with a modified version of the pre–pro 
HSA/MFα1 fusion leader sequence [30] consisting of the 
amino acid sequence MKWVFIVSILFLFSSAYSRSLDKR 
(referred to as mHSA/MFα1-leader) [18]. Addition-
ally, the 3′-end of the human albumin DNA was modi-
fied to introduce two TAA stop codons. pDB4692 was 
constructed by cloning the MET17 promoter in place of 
the PRB1 promoter in pDB4081. The DNA sequence of 
the MET17 promoter is −388 to −1 bps from the start 
codon of the MET17 gene on Chr. VII 732542–733876 
[GeneID:851010]. The hBD2 DNA fragment was cloned 
between the PRB1 promoter and the ADH1 termina-
tor in pDB4081 to replace the rHA gene and create 
pDB4146. The human β-defensin-2 sequence on Chr. 
8 7752099–7754237 was codon optimised for expres-
sion in S. cerevisiae and an additional TAA stop codon 
was applied to the sequence. pDB4351 was constructed 
by cloning the MET17 promoter into pDB4146 in place 
of the PRB1 promoter. The MET17 and PRB1 promot-
ers in pDB4146 and pDB4351 are linked to the MFα1 
Fig. 5 Growth of DYB7 and DB1 producing hBD2 or rHA. rHA and hBD2 were expressed using 2 µm expression plasmids containing either the 
MET17 or PRB1 promoter upstream of the coding regions. These plasmids were transformed into S. cerevisiae strain DB1 or DYB7. The transformed 
yeast were inoculated at OD600 = 0.15 into BMMD SFC with or without 1000 µM methionine and grown for 5 days, while OD600 measurements 
were done approximately every 24 h. Error bars indicate standard deviations (n = 3). a Growth of DYB7 [pDB3936:GR:pDB4351], which express hBD2 
from the MET17 promoter under non-repressing (0 µM methionine) and initially repressing conditions (1000 µM methionine). b Growth of DYB7 
[pDB3936:GR:pDB4146], which express hBD2 from the PRB1 promoter without methionine (0 µM methionine) and with methionine in the media 
initially (1000 µM methionine). c Growth of DB1 [pDB3936:GR:pDB4351], which express hBD2 from the MET17 promoter under non-repressing 
(0 µM methionine) and initially repressing conditions (1000 µM methionine). d Growth of DYB7 [pDB3936:GR:pDB4692], which express rHA from the 
MET17 promoter under non-repressing (0 µM methionine) and initially repressing conditions (1000 µM methionine)
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(mating factor alpha) leader sequence (MRFPSIFTAV-
LFAASSALAAPVNTTTEDETAQIPAEAVIGYLDLEG-
DFDVAVLPFSNSTNNGLLFINTTIASIAAKEEGVSLD, 
[GeneID:296148471]) fused to the plectasin pro sequence 
plus a Kex2 protease cleavage site, with the sequence 
APQPVPEAYAVSDPEAHPDDFAGMDANQLQKR. 
These expression cassettes were cloned into a 2 µm plas-
mid, pDB3936 derived from of pSAC35 [36] and trans-
formed into S. cerevisiae DB1 and DYB7 simultaneously 
for gap–repair recombination [37, 38]. In pDB3936, the 
LEU2 gene of pSAC35 has been truncated by replacing 
KpnI–NotI fragment with a synthetic linker, resulting in 
removal of the NotI site. Plasmids pDB4081, pDB4146, 
pDB4351 and pDB4692 contain the rHA or hBD2 
expression constructs flanked by DNA for homologous 
recombination with pDB3936. Gap-repair transformants 
harbouring yeast expression disintegration plasmids were 
obtained by introducing purified Acc65I-BamHI “gapped 
plasmid” DNA (pDB3936) and purified PvuI-NsiI “insert” 
DNA. Plasmids obtained through gap-repair were named 
on basis of the origin of the “gapped plasmid” (pDB3936) 
and the plasmid of the “insert” fragment (e.g. pDB4692) 
using the convention pDB3936:GR:pDB4692. The yeast 
strains and expression plasmids used in this study are 
listed in Tables 1 and 2, respectively.
Culture conditions
Shake flask cultures with 10 mL BMMD (buffered mini-
mal media dextrose [28]) were grown in 50  mL conical 
shake flasks to an OD600 of 1.5–2.5 at 30  °C, 200  rpm, 
25 mm orbit. 670 µM methionine was used in the hBD2 
expressing pre-cultures to repress hBD2 expression. The 
amount of this pre-culture required to inoculate the main 
culture at OD600 of 0.15 was calculated, pelleted by cen-
trifugation and washed with BMMD medium to elimi-
nate any methionine used in the pre-culture. This washed 
cell pellet was then resuspended in the appropriate vol-
ume of BMMD with the correct concentration of methio-
nine and grown for 5  days at 30  °C, 200  rpm in 50  mL 
conical shake flasks.
SDS–polyacrylamide gel electrophoresis (PAGE)
Culture supernatant was run on NuPAGE® 12% Bis–Tris 
gels (Invitrogen) in MES SDS running buffer at 200 V for 
35  min. The molecular weight standard used was See-
Blue® Plus2 Pre-stained protein standard (Invitrogen). 
Proteins were stained using InstantBlue (Expedeon).
Ultra‑performance liquid chromatography mass 
spectrometry (UPLC‑MS)
Chromatographic separation of culture supernatants 
was carried out on an ACQUITY UPLC system (Waters) 
using an ACQUITY UPLC BEH 300 Å C-18 column 
(2.1 mm id ×100 mm, particle size 1.7 μm) at 45 °C with 
a flow rate of 0.250 mL/min. The mobile phase consisted 
of 0.1% formic acid in Milli-Q H20 (solvent A) and 0.1% 
formic acid in acetonitrile (solvent B). The column was 
eluted using a gradient from 5% B to 45% B over 4 min 
and 30  s. The injection volume was 10  μL. UPLC col-
umn eluate was analysed by online electrospray ioniza-
tion-time of flight mass spectrometry using a calibrated 
micrOTOF II (Bruker) mass spectrometer in positive ion 
mode. Data were analysed for relative quantitation using 
DataAnalysis 4.0 (Bruker) software by extracting the ion 
chromatogram (EIC) for the 722 mass-to-charge (m/z) 
analyte. Charge state deconvolution, to confirm the intact 
mass of the analyte, was performed using the maximum 
entropy method.
Total DNA extraction
Strains were grown at 30  °C with shaking (200  rpm, 
25  mm orbit) for approximately 24  h in 10  mL BMMD 
medium with and without the appropriate methio-
nine concentration at 30  °C to an OD600 in the mid-log 
phase. Cells were harvested by centrifugation at 5000g 
for 5 min and stored at −80 °C. Total DNA was isolated 
using a Wizard® Genomic DNA isolation kit (Promega). 
DNA quantity was determined by A260 measurements 
and purity by A260/A280 ratio measurements using a 
NanoDrop 1000 UV–Vis spectrophotometer (Thermo 
Scientific).
Total RNA extraction and cDNA synthesis
Every 24 h 500 µL culture samples were taken and cells 
harvested by centrifugation at 13,000g for 2  min. The 
pellets were resuspended in 300  µL RNAlater (Qiagen) 
and stored at 4  °C for immediate stabilisation and pro-
tection of the RNA. Total RNA was extracted using 
the RNeasy Mini kit (Qiagen) with yeast spheroplasts 
Table 2 Description of plasmids used in this work
Plasmid Description
pDB3936 pSAC35, a 2 μm-derived yeast episomal expression vector 
with a truncated LEU2 [36]
pDB4081 Containing the expression cassette; PRB1 promoter, the 
mHSA/MFα1-leader leader, the coding sequence of rHA 
and the S. cerevisiae ADH1 transcription terminator
pDB4146 Containing the expression cassette; PRB1 promoter, the 
MFα1/plectasin leader, the coding sequence of hBD2 
and the S. cerevisiae ADH1 transcription terminator
pDB4351 Containing the expression cassette; MET17 promoter, the 
MFα1/plectasin leader, the coding sequence of hBD2 
and the S. cerevisiae ADH1 transcription terminator
pDB4692 Containing the expression cassette; MET17 promoter, the 
mHSA/MFα1-leader leader, the coding sequence of rHA 
and the S. cerevisiae ADH1 transcription terminator
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prepared by lyticase (Sigma) digestion. To eliminate 
genomic DNA contamination, an additional DNase 
treatment was performed according to the RNeasy kit 
instruction with the RNase-free DNase set (Qiagen). 
Quantity of the extracted RNA was determined by A260 
measurements and purity by A260/A280 ratio measure-
ments using a NanoDrop 1000 UV–Vis spectrophotom-
eter (Thermo Scientific). 100  ng DNase digested total 
RNA was used in a 20  μL Superscript III (Invitrogen) 
reverse transcriptase reaction mixture according to the 
manufacturer’s instructions.
Quantitative real time polymerase chain reaction (RT‑PCR)
TaqMan® primer/probe sequences were designed using 
Primer Express software (Applied Biosystems). Reac-
tions were set up in total volumes of 25 μL comprising 
12.5  μL of 2×  TaqMan® Gene Expression master mix 
(Applied Biosystems), 250 nM probe, 1 μM primers and 
5 μL of cDNA or DNA template (diluted 100-fold). The 
absence of genomic DNA contamination in RNA sam-
ples were checked by RT-PCR before cDNA synthesis 
using RNA as a template in RT-PCR (minus reverse tran-
scriptase control). Blank samples (no template control) 
were incorporated in each assay. Reactions were car-
ried out in triplicates and as singleplex reactions using 
an Applied Biosystems 7500 system with the thermocy-
cling program consisting of one hold at 50 °C for 2 min, 
another hold at 95 °C for 10 min, followed by 40 cycles 
of 15 s at 95 °C and 1 min at 60 °C. Transcript data were 
analysed using the relative standard curve method using 
TAF10 as endogenous control and gene copy-numbers 
were determined using FLP1 as the single-copy refer-
ence gene.
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